HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top

HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top

Non-small-cell lung cancer (NSCLC) can harbour different HER2 alterations: HER2 protein overexpression (2–35%), HER2 gene amplification (2–20%), and gene mutations (1–4%). The discovery of the HER2 gene in the 1980s raised great expectations for the treatment of several tumours. However, it was only...

Full description

Saved in:
Bibliographic Details
Main Authors: Pamela Trillo Aliaga, Gianluca Spitaleri, Ilaria Attili, Carla Corvaja, Elena Battaiotto, Panagiotis Agisilaos Angelopoulos, Ester Del Signore, Antonio Passaro, Filippo de Marinis
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Molecules
Subjects:
NSCLC
adenocarcinoma
HER2
ERBB2
targeted therapy
antibody–drug conjugate
Online Access:https://www.mdpi.com/1420-3049/30/12/2645
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items